OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
6
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Proteomics
(3)
Organisms
Homo sapiens
(2)
Pseudoalteromonas sp. A3
(1)
Repository
iProX
(3)
Publication Date
2023
(2)
2022
(1)
Release Date
2024
(1)
2022
(1)
2017
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Efficacy and safety of Xiangsha Liujunzi granules for functional dyspepsia: A multi-center randomized double-blind placebo-controlled clinical study.
Not available
S-EPMC5558122
|
biostudies-literature
Cite
Handelin alleviates cachexia- and aging-induced skeletal muscle atrophy by improving protein homeostasis and inhibiting inflammation.
Not available
S-EPMC10834327
|
biostudies-literature
Cite
Cost-Effectiveness of Presbyopia Correction Among Seven Strategies of Bilateral Cataract Surgery Based on a Prospective Single-Blind Two-Center Trial in China.
Not available
S-EPMC9587195
|
biostudies-literature
Cite
Green production of alginate oligosaccharides from Laminaria japonica root by fermentation of a Laminaria japonica-degrading strain Pseudoaltermonas sp. A3
To identify carbohydrate-active enzymes in the secretome of strain A3 when L. japonica was the sole carbon source and key alginate lyases in the supernatant of fermentation broth.
ORGANISM(S):
Pseudoalteromonas Sp. A3
2022-11-30
|
PXD037880
|
Cite
Identification the interactors of the K235-acetylated ALKBH5
The differntial gel band between wild-type ALKBH5-interacted proteins and K235R mutant ALKBH5-interacted proteins was identifed by mass spectrometry.
ORGANISM(S):
Homo Sapiens
2023-04-13
|
PXD020071
|
Cite
Identification of the acetylation sites in ALKBH5
The acetylation modification sites in ALKBH5 was identified by mass spectrometry.
ORGANISM(S):
Homo Sapiens
2023-04-13
|
PXD020070
|
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets